Company Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe.
It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).
The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 99 |
| CEO | Rick Winningham |
Contact Details
Address: 901 Gateway Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 808 6000 |
| Website | theravance.com |
Stock Details
| Ticker Symbol | TBPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001583107 |
| CUSIP Number | G8807B106 |
| ISIN Number | KYG8807B1068 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Aziz Sawaf C.F.A. | Senior Vice President and Chief Financial Officer |
| Stuart Knight | Senior Vice President of IT&I and Chief Information Officer |
| Gail B. Cohen | Vice President of Corporate Communications and Investor Relations |
| Brett A. Grimaud Esq. | Senior Vice President, General Counsel and Secretary |
| Rhonda F. Farnum | Chief Business Officer and Senior Vice President of Commercial and Medical Affairs |
| Stacy L. Pryce | Senior Vice President and Chief Strategy Officer |
| Dr. Aine Miller Ph.D. | SVice President of Dev., VP of Regu., Quality, Clinical Safety and Pharmacovigilance and Head of Ireland Office |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 23, 2024 | 8-K | Current Report |
| Sep 10, 2024 | 8-K | Current Report |
| Sep 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |